Drugs / Lu AF35700
last change Oct 2019 re-read 2 minutes ago

Lu AF35700

Developed for
schizophrenia · schizoaffective disorder
Investigated by
H. Lundbeck A/S

Trials 12 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 19 trials
Phase 1 NCT03670082 Sep → Dec 2018 H. Lundbeck A/S Completed No outcome recorded
Phase 1 NCT03241147 Jul 2017 → Jul 2019 kidney failure H. Lundbeck A/S Terminated No outcome recorded
Phase 1 NCT03195946 Jun 2017 → Jan 2018 hypersensitivity reaction disease H. Lundbeck A/S Completed No outcome recorded
Phase 1 NCT03189615 May 2017 → Feb 2018 H. Lundbeck A/S Completed No outcome recorded
Phase 1 NCT03103646 Mar 2017 → Apr 2019 H. Lundbeck A/S Completed No outcome recorded
Phase 1 NCT02901587 Sep 2016 → Apr 2018 schizoaffective disorder, schizophrenia H. Lundbeck A/S Completed No outcome recorded
Phase 1 NCT02333487 Dec 2014 → Feb 2016 schizophrenia H. Lundbeck A/S Completed No outcome recorded
Phase 1 NCT02093169 Feb → Jun 2014 H. Lundbeck A/S Completed No outcome recorded
Phase 1 NCT02202226 Jan 2013 → Feb 2015 schizophrenia H. Lundbeck A/S Completed No outcome recorded
Phase 33 trials
Phase 3 NCT03230864 Jul 2017 → Dec 2018 schizophrenia H. Lundbeck A/S Terminated No outcome recorded
Phase 3 NCT02892422 Aug 2016 → Oct 2019 schizophrenia H. Lundbeck A/S Completed No outcome recorded
Phase 3 NCT02717195 Apr 2016 → Aug 2018 schizophrenia H. Lundbeck A/S Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as Lu AF35700 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02892422
11

NCT03189615

NCT02202226

NCT03103646

NCT02717195

NCT02333487

NCT03670082

NCT02093169

NCT02901587

NCT03241147

NCT03230864

NCT03195946

Route Oral orally” NCT02093169